October 2019, Volume 5, Issue 12

October 2019

Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.

Table of Contents

October 2019 Issue

A Leiden Wild Card

Tuesday, October 1st, 2019
In our August 2019 issue, Leslie J. Raffini, MD, responded to a colleague seeking advice on managing large venous thromboembolisms (VTEs) in two teenaged...

Trigger Warning

Tuesday, October 1st, 2019
In our August 2019 issue, two hematologists debated whether gun violence should be considered a public health issue and, by extension, whether physicians should...

Fathers (and Mothers) of Hematology

Tuesday, October 1st, 2019
In 1963, Boston hematologist William Dameshek wrote an essay in the journal he’d founded 17 years earlier, Blood, describing 18th-century English anatomist William Hewson’s detailed...

October 2019 Issue

ASH Directions

ASH Clinical News Now Available on the ASH Publications App, ABIM Changing Maintenance of...

Tuesday, October 1st, 2019
ASH Clinical News Now Available on the ASH Publications App The American Society of Hematology (ASH) Publications app provides access to content from Blood, Blood...
The Society Pages

Remembering Stanley Schrier, John Hansen, and more

Tuesday, October 1st, 2019
Remembering Stanley Schrier (1929 – 2019) Stanley Schrier, MD, a former American Society of Hematology (ASH) president who spent nearly 60 years at Stanford University’s...

October 2019 Issue

Dr. Kyle at the Mayo Clinic.

Pulling Back the Curtain: Robert A. Kyle, MD

Tuesday, October 1st, 2019
In this edition, Robert A. Kyle, MD, chronicles his nearly 70-year career and rural beginnings, from attending a one-room schoolhouse in North Dakota to...

The Other Opioid Epidemic

Tuesday, October 1st, 2019
Federal crackdowns on opioid prescribing have shifted the crisis from overdoses to undertreatment The United States is in the grip of an opioid epidemic that...

More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma

Tuesday, October 1st, 2019
As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...

October 2019 Issue

You Make the Call

Reader Responses: How would you treat a patient with a prolonged PTT and antiphospholipid...

Tuesday, October 1st, 2019
Here’s how readers responded to a You Make the Call question about a patient with a prolonged PTT and antiphospholipid antibodies. Disclaimer: ASH does not...
You Make the Call

How would you treat a patient with a prolonged PTT and antiphospholipid antibodies?

Tuesday, October 1st, 2019
This month, Caroline Berube, MD, discusses treatment for a patient with a prolonged PTT and antiphospholipid antibodies. And don't forget to check out next month's...

October 2019 Issue

Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia

Tuesday, October 1st, 2019
In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...
WIB_icon

Pegylated Interferon Leads to High Response Rates in Essential Thrombocythemia and Polycythemia Vera After...

Tuesday, October 1st, 2019
According to results of a phase II study published in Blood, treatment with pegylated-interferon-α (PEG-rIFN-α) was associated with an overall response rate (ORR) of...

FDA Approves Ferric Maltol for Treatment of Iron Deficiency

Tuesday, October 1st, 2019
The U.S. Food and Drug Administration (FDA) announced its approval of oral ferric maltol for the treatment of iron deficiency in adults. Ferric maltol is...

Clofarabine Plus Cytarabine May Provide Less Toxic Option for Newly Diagnosed Pediatric Patients With...

Tuesday, October 1st, 2019
For children newly diagnosed with acute myeloid leukemia (AML), treatment with a combination of clofarabine plus cytarabine was associated with similar survival rates when...

Rivipansel Fails to Meet Phase III Trial Endpoints

Tuesday, October 1st, 2019
In a pivotal phase III trial, rivipansel failed to meet its primary and secondary efficacy endpoints in patients with sickle cell disease (SCD) who...

Can ICH Survivors Safely RESTART Antiplatelet Therapy?

Tuesday, October 1st, 2019
While treatment with antiplatelet therapy lessens the risks of subsequent occlusive vascular events, it may increase the risk of recurrent intracerebral hemorrhage (ICH) in...

Roxadustat Improves Hemoglobin Levels and Response Rates in Patients With Anemia Related to Chronic...

Tuesday, October 1st, 2019
According to results from a phase III trial, roxadustat increased hemoglobin levels and hemoglobin response rates, compared with placebo, in patients with anemia and...

Genetic Testing and Drug Companies Partner to Develop New Medicines

Tuesday, October 1st, 2019
Since its launch, 23andMe has provided more than 8 million customers with information about their ancestry and predisposition to developing certain diseases. Now, a...

CMS Increases Payment, Access to CAR T-Cell Therapy

Tuesday, October 1st, 2019
The Centers for Medicare and Medicaid Services (CMS) announced two policy changes that should improve access to chimeric antigen receptor (CAR) T-cell therapies: First,...

Textured Breast Implants Recalled by FDA Over Cancer Risk

Tuesday, October 1st, 2019
The U.S. Food and Drug Administration (FDA) has requested that pharmaceutical company Allergan recall its BIOCELL textured breast implants due to a risk of...

October 2019 Issue

On location

Two Studies Support Using Concizumab as Prophylaxis in Patients With Hemophilia

Tuesday, October 1st, 2019
Concizumab could be a safe and effective subcutaneous prophylactic treatment option for patients with hemophilia A or B with or without inhibitors, according to...
On location

Hemophilia B: The Next Target for Gene Therapy?

Tuesday, October 1st, 2019
Treatment with a single dose of AMT-061, an investigational gene therapy, led to increased factor IX (FIX) activity and reduced spontaneous bleeding episodes for...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?

Tuesday, October 1st, 2019
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...

Tuesday, October 1st, 2019
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...

Tuesday, October 1st, 2019
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

SHARE